A Double-Masked Three-Month Comparison Between 0.25% Betaxolol Suspension and 0.5% Betaxolol Ophthalmic Solution

Weinreb, Robert N.; Caldwell, David S.; Goode, Stephen M.; Horwitz, Barry; Laibovitz, Robert; Shrader, C. Eric; Stewart, Robert H.; Williams, A. Thomas

doi:10.1016/s0002-9394(14)76990-9

Cited by 36 publications

(18 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…then the authors prefer to use betaxolol (a β 1-selective drug), The IOP alone may not be sufficient to exclude or confirm that starting with the lowest dose (0.25%) [12] and observing the patient the child has glaucoma. Infant sclera is elastic and, as such, raised after the first dose.…”

Section: Measurement Of Intraocular Pressurementioning

confidence: 99%

“…Occlusion of the nasolacrimal system with combined preparation, observation for systemic adverse reactions finger pressure over the medial canthus for 3-4 minutes is thought would be prudent. [12,14] to reduce systemic absorption by as much as 40%. [11,44,45] HowevIt is essential that the prescribing clinician is aware of potential er, the practicalities of maintaining pressure over the medial adverse effects and how they may present, so that the child's carers canthus for 3-4 minutes for each eye, for every eye drop adminiscan be warned of signs to look for.…”

Section: Combined Preparationsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacologic Management of Glaucoma in Childhood

Moore

Nischal

2007

Pediatric Drugs

View full text Add to dashboard Cite

An evidence-based review of the drugs available for the medical management of childhood glaucoma is presented; almost all of the drugs are not licensed for use in children. Despite this, most topical drugs are safe; however, there are some significant exceptions, such as brimonidine, which may cause apnea, among other life-threatening adverse events, in infants. Broad families of drugs are available including topical adrenoceptor antagonists, topical and systemic carbonic anhydrase inhibitors, prostaglandin analogs, adrenoceptor agonists, parasympathomimetics, and combination preparations. These drugs help to reduce intraocular pressure by reducing aqueous production or increasing the outflow facility. The variety of anti-ocular hypertensive medications for childhood glaucoma has increased in recent years. The vast majority of data on these medications are from adult studies but each year more experience of their use in pediatric glaucoma is gained. In general, topical treatment is well tolerated; however, the prescribing clinician and carers should be aware of potential adverse effects and how they may present.

show abstract

Section: Measurement Of Intraocular Pressurementioning

confidence: 99%

Section: Combined Preparationsmentioning

confidence: 99%

Pharmacologic Management of Glaucoma in Childhood

Moore

Nischal

2007

Pediatric Drugs

View full text Add to dashboard Cite

show abstract

“…Results of all 3 treatments compare favorably with those seen in the adult studies (4.7, 5.0, and 4.8 mm Hg for betaxolol 0.25%, TGFS 0.25%, and TGFS 0.5%, respectively). [15][16][17] The majority of subjects enrolled (67%) were on a topical IOP-lowering medication(s) at study entry, most commonly beta-blockers resulting in lower baseline IOPs due to the absence of a washout phase, which would likely reduce the absolute response to study drug. Although many of the subjects entering the study were on more than 1 medication (average 1.4), evaluation of the exit IOPs demonstrated a reduction in mean IOP from baseline at trough (approximately 12 hours postdose for betaxolol and approximately 24 hours postdose for TGFS 0.25% and TGFS 0.5%) of 1.8, 1.8, and 3.7 mm Hg for betaxolol 0.25% (N 5 20), TGFS 0.25 (N 5 22), and TGFS 0.5% (N 5 28), respectively.…”

Section: Discussionmentioning

confidence: 99%

Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: A randomized clinical trial

Plager

Whitson

Netland

et al. 2009

Journal of American Association for Pediatric Ophthalmology and

View full text Add to dashboard Cite

“…0.25% BETOPTIC S Ophthalmic Suspension formulation in its unique ophthalmic delivery system has shown clinical effectiveness in lowering intraocular pressure statistically equivalent to the BETOPTIC 0.5% Sterile Ophthalmic Solution in a large controlled, parallel clinical study (27). CONCLUSION 0.25% BETOPTIC S Ophthalmic Suspension is a novel localized drug delivery system utilizing ion exchange resins to deliver Betaxolol.…”

Section: Bioavailaj3ilily_sludymentioning

confidence: 91%

Ion Exchange Resins for Ophthalmic Delivery

Jani

Gan²,

Ali³

et al. 1994

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

A new novel delivery system for ophthalmic drugs was developed using an antiglaucoma agent Betaxolol Hydrochloride as a model. The new delivery system involved both the binding and release of drug from ion exchange resin particles. Betaxolol was studied in-vitro via a release model analysis. The ocular comfort of Betaxolol was greatly enhanced by reducing the availability of free drug molecules in the precorneal tear film. The amount of resin concentration was selected to obtain optimum binding of the drug. The zeta potential of suspended particles was adjusted to produce flocculated suspension. Drug resin particles were then incorporated into the structured vehicle, containing Carbomer 934P as a polymer, to enhance the physical stability and ease of resuspendability of the product. This delivery system also optimized the bioavailability of Betaxolol, reducing the total drug concentration in half to 0.25% Betaxolol in 0.25% BETOPTIC S Ophthalmic Suspension as compared with 0.5% Betaxolol in BETOPTIC 0.5% Sterile Ophthalmic Solution dosage form. Increased comfort of 0.25% BETOPTIC S Ophthalmic Suspension, as well as its bioequivalency data in animal models (rabbits), was confirmed in actual clinical trials of the product 0.25% BETOPTIC S Ophthalmic Suspension. The 0.25% BETOPTIC S Ophthalmic Suspension product has been approved by FDA and is marketed in U. S. since February 1990. The 0.25% BETOPTIC S Ophthalmic Suspension formulation has an increased bioavailability (equivalent to BETOPTIC 0.5% Sterile Ophthalmic Solution at half the concentration of drug); and pharmaceutically, is an elegant suspension product which settles slowly providing uniform dosage and increased ocular comfort.

show abstract

A Double-Masked Three-Month Comparison Between 0.25% Betaxolol Suspension and 0.5% Betaxolol Ophthalmic Solution

Cited by 36 publications

References 17 publications

Pharmacologic Management of Glaucoma in Childhood

Pharmacologic Management of Glaucoma in Childhood

Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: A randomized clinical trial

Ion Exchange Resins for Ophthalmic Delivery

Contact Info

Product

Resources

About